Johnson & Johnson announced positive Phase 2b COPERNICUS study results showing low rates of rash, blood clots, and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in treating advanced non-small cell lung cancer with EGFR mutations. The study involved 214 diverse patients and demonstrated fewer than 1% treatment discontinuations due to related adverse events at one year, improving on previous intravenous treatment data. These findings support RYBREVANT FASPRO plus LAZCLUZE as a first-line treatment option with a better patient experience through less frequent dosing and prophylactic care. The study reflects Johnson & Johnson's commitment to advancing cancer treatment delivery and management in real-world settings.
Johnson & Johnson (JNJ) shares are trading at USD 266.32 as of September 15, 2026, 09:51 WIB, just below their 52-week high of USD 278.43, showing resilience in the health sector. The stock's 1-day gain of 0.28% contrasts with its 52-week low of USD 174.16, highlighting strong market confidence possibly supported by positive clinical trial news like the COPERNICUS study. With a market cap of $640.02 billion and a dividend yield of 2.02%, JNJ remains a significant player in healthcare innovation and investment.
Johnson & Johnson has achieved its 64th consecutive year of dividend increases, raising its quarterly dividend by 3.1% to $1.34 per share in 2026. Despite strong overall sales growth driven by new drugs like Tremfya and Darzalex, the company faces si...
With market risks rising in October 2026, five elite dividend stocks in healthcare, consumer staples, and utilities are highlighted for their resilience during downturns. These stocks, including Coca-Cola, Johnson & Johnson, McDonald's, NextEra Energ...
Procter & Gamble leads with 70 years of consecutive dividend increases, joined by Johnson & Johnson, Coca-Cola, ADP, and Lowe's, each maintaining solid payout ratios and strong cash flow coverage. These companies demonstrate resilience through recess...
Johnson & Johnson and Procter & Gamble are both Dividend Kings with similar valuations, but Johnson & Johnson is favored for long-term dividend growth due to better dividend coverage, lower payout ratio, and stronger growth prospects despite P&G's lo...
